Kura Oncology

Historical price data

Kura Oncology's mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. Founded in 2014, the company leverages deep scientific understanding of cancer biology to develop targeted therapies for areas of high unmet need, including head and neck cancer, lung cancer, and acute leukemias. Kura's strategy involves investigating its therapies in combination with standards of care to forge new paths for durable remissions. The company is led by an experienced team and is publicly traded on NASDAQ under the ticker KURA.

Precision oncology platform focused on developing small molecule inhibitors targeting specific oncogenic pathways, with a historical emphasis on the RAS pathway and farnesyltransferase inhibition.

21 drugs in pipeline, 1 in Phase 3

Kura faces competition from large pharma oncology portfolios and other biotechs in targeted therapy. In HNSCC, competitors include checkpoint inhibitors (Keytruda, Opdivo). In the RAS pathway space, direct KRAS G12C inhibitors (Lumakras, Krazati) are competitors, though targeting different nodes. Kura aims to differentiate by focusing on specific subsets like HRAS-mutant cancers and combination approaches.